Summary of clinical results
DUCRAY

Efficacy of KERACNYL serum in the maintenance phase of acne
Efficacy of KERACNYL serum in the maintenance phase of acne in adult women, under dermatological control.
Randomized, single-blind, multicenter, controlled clinical trial versus comparator.
Population
52 women aged 25-50 with mild to moderate facial acne, either completely healed or nearly healed, according to the Investigator's Global Assessment (IGA) criteria
Adult female acne requiring topical medication - For at least 12 weeks - Stopped at least 7 days before study
Application of KERACNYL serum
2 groups:
- KERACNYL SERUM (n=26) : Application once or twice a day to the face for 4 months
- LIGHT HYDRATING CREAM (n=26): Application once or twice a day to the face for 4 months
Evaluation criteria
- Time to recurrence of acne (need to reintroduce topical treatment)
- Change in severity: total number of acne lesions & number of post-inflammatory lesions
- Evolution of quality of life (Acne-QoL questionnaire)
- Skin tolerance
Results
- Reduced recurrence rate of facial acne versus comparator over 4 months

- Significant decrease in the number of acne lesions compared to the first visit: -48% at 2 months, -50% at 3 months and -51% at 4 months

- Significant decrease in the number of acne lesions compared to comparator product
- Significant decrease in the number of post-inflammatory hyperpigmented lesions from 3 months
- Significant decrease in the number of post-inflammatory erythematous lesions from 2 months
- Significant improvement in quality of life
- Excellent to good global tolerance for 89% of patients
Conclusion
- Reduced rate of facial acne recurrence
- Effective on acne and post-inflammatory lesions
- Good tolerance
More summaries of clinical results
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.